Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | MIF | P14174 | 1/20 | 0.81 |
| ▸ | PDE4A | P27815 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 6/20 | 0.35 |
| ▸ | BRD1 | O95696 | 6/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MLNR | O43193 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iguratimod SCHEMBL29366981 | 0.90 | PTGS1 (1.00) | PTGS1ADORA3MIFPDE4APDE4D | |
| Iguratimod SCHEMBL26326 | 0.90 | PTGS1 (1.00) | PTGS1ADORA3MIFPDE4APDE4D | |
| Iguratimod SCHEMBL5455197 | 0.89 | PTGS1 (0.98) | PTGS1ADORA3MIFPDE4APDE4D | |
| Iguratimod SCHEMBL29230458 | 0.84 | PTGS1 (0.87) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL31114276 | 0.83 | PTGS1 (0.77) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL8288071 | 0.83 | ADORA3 (0.74) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL30753982 | 0.83 | PTGS1 (0.77) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL8295858 | 0.82 | ADORA3 (0.71) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL10417305 | 0.82 | PTGS1 (0.85) | PTGS1ADORA3MIFPDE4APDE4D | |
| SCHEMBL10416928 | 0.80 | PTGS1 (0.76) | PTGS1ADORA3MIFPDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9918963-B2 | Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | claimed |
| EP-3078372-B1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO LTD (JP) | 2017-09-13 | — | — | EP | claimed |
| EP-3078372-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-10-12 | — | — | EP | claimed |
| US-20160228406-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| US-20160228404-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| US-20150353519-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-12-10 | — | — | US | claimed |
| EP-2929880-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | Toyama Chemical Co., Ltd. (JP) | 2015-10-14 | — | — | EP | claimed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| US-9918963-B2 | Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-3078372-B1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO LTD (JP) | 2017-09-13 | — | — | EP | disclosed |
| EP-3078372-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-10-12 | — | — | EP | disclosed |
| US-20160228406-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160228404-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20150353519-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228404-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, ARG1, MSR1 | PTGS1 846/4885ADORA3 3285/4885MIF 1/4885 |
| US-20160228406-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MMP12, CCL2 | PTGS1 274/4885ADORA3 3064/4885MIF 1/4885 |
| US-20150353519-A1 | THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MSR1, ARG1 | PTGS1 108/4885ADORA3 3011/4885MIF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.